444 related articles for article (PubMed ID: 33872050)
21. Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
Reignier PL; Gauthier H; Hennequin C; Aussedat Q; Xylinas E; Desgrandchamps F; Culine S; Masson-Lecomte A; Dumont C
World J Urol; 2023 Nov; 41(11):3249-3255. PubMed ID: 37410102
[TBL] [Abstract][Full Text] [Related]
22. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
[TBL] [Abstract][Full Text] [Related]
23. Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England.
John JB; Varughese MA; Cooper N; Wong K; Hounsome L; Treece S; McGrath JS; Harden S
Eur Urol Focus; 2021 Mar; 7(2):359-365. PubMed ID: 32088138
[TBL] [Abstract][Full Text] [Related]
24. Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer.
Kohut-Jackson A; Orf J; Barresi D; Davaro F; Hamilton Z
Urol Oncol; 2024 May; 42(5):160.e25-160.e31. PubMed ID: 38238117
[TBL] [Abstract][Full Text] [Related]
25. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
[TBL] [Abstract][Full Text] [Related]
27. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
Lane G; Risk M; Fan Y; Krishna S; Konety B
BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
[TBL] [Abstract][Full Text] [Related]
28. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
[TBL] [Abstract][Full Text] [Related]
29. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
[TBL] [Abstract][Full Text] [Related]
30. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
31. Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy.
Nassiri N; Ghodoussipour S; Maas M; Nazemi A; Asanad K; Pearce S; Bhanvadia SS; Djaladat H; Schuckman A; Daneshmand S
Urology; 2020 Aug; 142():155-160. PubMed ID: 32268173
[TBL] [Abstract][Full Text] [Related]
32. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
[TBL] [Abstract][Full Text] [Related]
33. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
34. Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.
Posielski N; Koenig H; Ho O; Porter C; Flores JP
Oncology (Williston Park); 2022 Jan; 36(1):21-33. PubMed ID: 35089670
[TBL] [Abstract][Full Text] [Related]
35. Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Tarrel R; Quevedo FJ; Cheville JC; Karnes RJ
World J Urol; 2019 Nov; 37(11):2409-2418. PubMed ID: 30805684
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
[TBL] [Abstract][Full Text] [Related]
37. Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
van Hoogstraten LMC; Man CCO; Witjes JA; Meijer RP; Mulder SF; Smilde TJ; Ripping TM; Kiemeney LA; Aben KKH;
World J Urol; 2023 Jul; 41(7):1837-1845. PubMed ID: 37258902
[TBL] [Abstract][Full Text] [Related]
38. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.
Reardon ZD; Patel SG; Zaid HB; Stimson CJ; Resnick MJ; Keegan KA; Barocas DA; Chang SS; Cookson MS
Eur Urol; 2015 Jan; 67(1):165-170. PubMed ID: 24472710
[TBL] [Abstract][Full Text] [Related]
39. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
[No Abstract] [Full Text] [Related]
40. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
